



SeraGene Therapeutics Inc.

SeraGene Therapeutics harnesses nanomedicine technologies to develop the next generation of hematological therapies that can improve patient health and quality of life, while reducing burden on the healthcare system.


Core Technology

SeraGene uses two complementary approaches to achieve custom control of circulating proteins in blood:

- 1) Controlling the expression of coagulation proteins secreted from the liver
- 2) Engineering blood cells by modulating resident protein pools

SeraGene's therapeutics can manage coagulation disorders by targeting specific proteins.

SeraGene Therapeutics Inc.
Vancouver, BC, Canada
a.stirilchuk@seragenetx.com



Market Opportunity

SeraGene's RNA-based therapies provide **prolonged protection** against bleeding, inflammation, and thrombosis.



RNA therapies can last for weeks after a single dose – over 10x longer than some standards of care.



Long-lasting protection improves quality of life, stops chronic health deterioration, and reduces treatment time.

SeraGene's therapies represent transformational opportunities for the industry and for patients underserved by current treatments.



SeraGene provides a much needed option for historically overlooked groups, including those with rare disorders and women with bleeding disorders.



These complementary approaches improve the safety of current treatments and support the use of gene therapies.

RNA THERAPIES >> TO TREAT BLEEDING DISORDERS & THROMBOSIS

SeraGene's RNA agents are targeted to provide long-lasting protection.

Leadership



Amy Strilchuk
Chief Executive Officer



Lin Jiin Juang
Chief Science Officer



Christian Kastrup
Board Chair



Pieter Cullis
Co-Founder/Board Member



Katherine Badior
Co-Founder/Board Member

